Protara Therapeutics, Inc. (NASDAQ:TARA) Receives $20.50 Average Target Price from Brokerages

Protara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) has received a consensus recommendation of "Buy" from the seven brokerages that are currently covering the stock, Marketbeat reports. Six analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $20.50.

TARA has been the topic of a number of research reports. Jones Trading raised shares of Protara Therapeutics to a "strong-buy" rating and set a $21.00 price target on the stock in a research note on Thursday, May 22nd. Lifesci Capital began coverage on Protara Therapeutics in a research note on Tuesday, March 11th. They set an "outperform" rating and a $22.00 price target for the company. Scotiabank started coverage on Protara Therapeutics in a report on Wednesday, April 16th. They set a "sector outperform" rating and a $12.00 price target for the company. HC Wainwright restated a "buy" rating and issued a $23.00 price objective on shares of Protara Therapeutics in a report on Monday, April 28th. Finally, Cantor Fitzgerald assumed coverage on Protara Therapeutics in a report on Friday, March 14th. They set an "overweight" rating on the stock.

Institutional Trading of Protara Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TARA. Charles Schwab Investment Management Inc. bought a new stake in shares of Protara Therapeutics in the first quarter valued at approximately $64,000. HBK Investments L P acquired a new stake in Protara Therapeutics during the fourth quarter worth about $106,000. Squarepoint Ops LLC bought a new position in Protara Therapeutics during the fourth quarter valued at about $110,000. Dimensional Fund Advisors LP bought a new position in Protara Therapeutics during the fourth quarter valued at about $111,000. Finally, American Century Companies Inc. acquired a new position in Protara Therapeutics in the 1st quarter valued at approximately $154,000. Institutional investors and hedge funds own 38.13% of the company's stock.

Protara Therapeutics Trading Up 4.5%

NASDAQ:TARA traded up $0.13 on Monday, hitting $2.91. 132,855 shares of the company's stock traded hands, compared to its average volume of 794,153. The company has a market cap of $112.12 million, a PE ratio of -1.69 and a beta of 1.35. Protara Therapeutics has a 1 year low of $1.60 and a 1 year high of $10.48. The firm has a 50-day moving average price of $3.24 and a 200-day moving average price of $4.06.

Protara Therapeutics (NASDAQ:TARA - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.18. On average, research analysts forecast that Protara Therapeutics will post -3.32 EPS for the current fiscal year.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.